Management of hepatitis B reactivation in patients receiving cancer chemotherapy-Reference-Cited by-同舟云学术

Management of hepatitis B reactivation in patients receiving cancer chemotherapy

Published:2012-06-12 Issue:5 Volume:5 Page:359-370
ISSN:1756-2848
Container-title:Therapeutic Advances in Gastroenterology
language:en
Short-container-title:Therap Adv Gastroenterol

Author:

Huang Yi-Wen¹²³⁴,Chung Raymond T.⁵

Affiliation:

1. Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

2. Liver Center, Cathay General Hospital Medical Center, Taipei, Taiwan

3. School of Medicine, Taipei Medical University, Taipei, Taiwan

4. Division of Gastroenterology, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan

5. Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Warren 1007, 55 Fruit Street, Boston, MA 02114, USA

Abstract

Hepatitis B virus (HBV) reactivation is well documented in previously resolved or inactive HBV carriers who receive cancer chemotherapy. The consequences of HBV reactivation range from self-limited conditions to fulminant hepatic failure and death. HBV reactivation also leads to premature termination of chemotherapy or delay in treatment schedules. This review summarizes current knowledge of management of HBV reactivation in patients receiving cancer chemotherapy. HBV surface antigen (HBsAg) testing should be performed in patients who require cancer chemotherapy. Four meta-analyses support lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients. Randomized controlled trials to compare different HBV antiviral agents are needed to define optimal regimens for the prevention and treatment of HBV reactivation in patients receiving cancer chemotherapy.

Publisher

SAGE Publications

Subject

Gastroenterology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1756283X12450245

Reference78 articles.

1. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours

2. American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases

3. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

4. Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients

5. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency Evaluation;Cancer Research Communications;2023-09-28

2. Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis;Frontiers in Oncology;2023-01-16

3. Case Report: In Situ Vaccination by Autologous CD16+ Dendritic Cells and Anti-PD-L 1 Antibody Synergized With Radiotherapy To Boost T Cells-Mediated Antitumor Efficacy In A Psoriatic Patient With Cutaneous Squamous Cell Carcinoma;Frontiers in Immunology;2021-12-23

4. Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan;JAMA Network Open;2021-04-06

5. AN UNUSUAL CASE OF HBV REACTIVATION IN A PATIENT WITH CHOLANGITIS AND CHOLEDOCHO-LITHIASIS UNDERGONE TO ERCP. A CASE REPORT;ACTA MEDICA MEDITERR;2020